Core Viewpoint - The company, Hualan Biological, has successfully completed Phase I/II clinical trials for its recombinant Exendin-4-FC fusion protein injection, a treatment for type 2 diabetes, and is preparing to initiate Phase III trials [2] Group 1 - The company has obtained complete efficacy and safety data from the completed clinical trials [2] - Hualan Biological is applying for a new indication for overweight/obesity and has communicated with the National Medical Products Administration, which has accepted the registration application [2]

Core Viewpoint - The company has successfully completed Phase I/II clinical trials for its recombinant Exendin-4-FC fusion protein injection, which is a treatment for type 2 diabetes, and is preparing to initiate Phase III clinical trials [1] Group 1: Product Development - The company is developing a new indication for its drug targeting overweight/obesity and has submitted a registration communication to the National Medical Products Administration, which has been accepted [1]